Skip to main content
. 2023 Oct 31;30(10):1776–1787. doi: 10.1093/ibd/izad245

Figure 2.

Figure 2.

Time to switching, discontinuation, or the end of study period in (A) Crohn's disease: first line, (B) Crohn's disease: second line, (C) ulcerative colitis: first line, and (D) ulcerative colitis: second line. ADA, adalimumab; CI, confidence interval; IFX, infliximab; UST, ustekinumab; VDZ, vedolizumab.